Your browser doesn't support javascript.
loading
Bioelectrical impedance analysis in the BaSAlt cohort-study: the phase angle as an additional parameter for sarcopenia quantification among German nursing home residents?
Haigis, Daniel; Wagner, Silas; Thiel, Ansgar; Nieß, Andreas M.
Afiliación
  • Haigis D; Department of Sports Medicine, University Hospital of Tuebingen, 72076, Tübingen, Germany. daniel.haigis@med.uni-tuebingen.de.
  • Wagner S; Interfaculty Research Institute for Sport and Physical Activity, University of Tuebingen, 72074, Tübingen, Germany. daniel.haigis@med.uni-tuebingen.de.
  • Thiel A; Department of Sports Medicine, University Hospital of Tuebingen, 72076, Tübingen, Germany.
  • Nieß AM; Interfaculty Research Institute for Sport and Physical Activity, University of Tuebingen, 72074, Tübingen, Germany.
Eur Geriatr Med ; 14(3): 537-546, 2023 06.
Article en En | MEDLINE | ID: mdl-37052833
PURPOSE: Sarcopenia is characterized by the loss of muscle mass, strength, and physical functioning. The bioelectrical impedance analysis (BIA) is a simplify method for the measurement of muscle quantity and quality. But there is a lack of evidence in the interpretation of the muscle quality parameter phase angle (PhA), which was recommended by the European Working Group on Sarcopenia in Older People 2 (EWGSOP2). We hypothesize that the PhA shows differences between sarcopenia categorized groups and can be used as an additional parameter for sarcopenia quantification among residents of nursing homes (NH). METHODS: Based on EWGSOP2 specifications, 78 residents from five German NH was categorized into sarcopenia groups. Group comparisons with Kruskal-Wallis tests, Dunn-Bonferroni post-hoc-Tests, and correlations with Spearman coefficients were conducted with the muscle quality parameter PhA. RESULTS: Significant group differences by Kruskal-Wallis test for PhA was detected (H = 8.150, p = 0.017). The Dunn-Bonferroni post-hoc-Test showed significant results by group comparison for "confirmed/ severe sarcopenia" (4.1° [3.1-5.0]) with "no sarcopenia" (4.6° [3.7-11.2]; p =0 .049) and "probable sarcopenia" (4.7° [3.4-13.5]; p = 0.016), respectively. CONCLUSIONS: There is a limitation for differentiation in preliminary stage of sarcopenia among multimorbid NH residents by PhA. Moreover, further research for specific cut-off-values and the individual sarcopenia progression monitoring by PhA are needed. TRIAL REGISTRATION: No. AZ A2.5.4-096_aa (Date of approval: July 2019).
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sarcopenia Tipo de estudio: Etiology_studies / Observational_studies Límite: Aged / Humans Idioma: En Revista: Eur Geriatr Med Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sarcopenia Tipo de estudio: Etiology_studies / Observational_studies Límite: Aged / Humans Idioma: En Revista: Eur Geriatr Med Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza